Mechanisms of Caspase-1 Mediated Schwannoma Regression
Mechanisms of Caspase-1 Mediated Schwannoma Regression
批准号:
9125667
负责人:
GARY JAY BRENNER
金额:
$36.38万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-30 至 2018-07-31
关键词:
AnimalsApoptosisApoptoticBenignBiochemicalBiologicalBiological AssayBiologyBystander EffectCASP1 geneCaspaseCause of DeathCell DeathCell LineageCellsCessation of lifeClinicalCodeCulture MediaDNADataDependovirusDevelopmentDiseaseDisease ManagementElementsEnvironmentGenesGoalsGrantHereditary DiseaseHumanImageImmuneImmune responseImmunocompetentImplantIn VitroInfectionInflammatoryInjection of therapeutic agentInvestigationLeadLesionLocationMagnetic Resonance ImagingManuscriptsMediatingMedicalModelingMolecularMonitorMusMyelin SheathNF1 geneNatural Killer CellsNeoplasmsNerveNeurilemmomaNeurofibromatosesNeurofibromatosis 2NeuronsNon-MalignantNude MicePathway interactionsPatientsPeripheral NervesPeripheral Nervous System NeoplasmsPrimary NeoplasmPublishingResearchResistance to infectionSchwann CellsSchwannomatosisStreamTechniquesTestingTherapeuticTherapeutic EffectTimeToxic effectTreatment EfficacyTumor VolumeTumor-DerivedViral VectorVirusadaptive immunityadeno-associated viral vectorcytokinedisabilityexosomegene therapy clinical trialimplantationin vivoindividual patientinnovationkillingsmicrovesiclesmyelinationneoplastic cellneurotoxicitynovelnovel therapeutic interventionnovel therapeuticspreclinical studypromoterprotein complexresponsesciatic nervetreatment strategytumortumor growthvectorvector control
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): While schwannoma tumors are typically benign (non-malignant) they can have devastating consequences for patients. As for an individual patient there is often no efficacious treatment. Thus, schwannoma therapy represents a major unmet clinical need. We have developed a new therapeutic approach to these nerve-associated tumors that involves intra-tumoral injection of an adeno-associated virus (AAV) vector carrying the pro-apoptotic gene caspase-1 (ICE) under a Schwann-cell specific promoter (P0); the vector is denoted AAV-P0-ICE. Our pre-clinical studies have shown a remarkable ability of the AAV-P0- ICE vector to produce a prolonged reduction in tumor volume with no nerve damage (manuscript submitted). Our preliminary data suggests that AAV-PO-ICE not only directly kills infected caspase-1-expressing tumor cells (presumably by inducing apoptosis), but also kills non-infected tumor cells through a "bystander" effect. It is hypothesize that this bystander killin is mediated by both tumor- and host-specific mechanisms that involve humoral- and cell-mediated pathways. The overriding goal is to investigate the biology of AAV-P0-ICE mediated tumor destruction in the human and mouse schwannoma models we have developed in nude and immunocompetent mice, respectively, and to identify the molecular and cellular pathways mediating the killing of non-vector-infected tumor cells that is associated with apoptotic death of
infected tumor cells. In brief, the specific aims are to 1) investigate the parameters of tumor regression in two schwannoma models in mice - a human schwannoma in nude mice and a mouse schwannoma in immune competent animals, 2) investigate whether caspase-1 bystander killing involves apoptotic death of uninfected cells, and 3) analyze whether host immune mechanisms are involved in AAV-P0-ICE initiated bystander killing. In vivo tumor growth will be monitored via bioluminescent imaging and MRI for the human and mouse schwannoma models, respectively; both techniques allow serial assessment over time in a given animal. A variety of biochemical and cell biological techniques will be used to determine whether caspase expressing tumor cells produce factors - both humoral and microvesicle contained - that can be transferred to and cause apoptotic death of uninfected tumor cells. Histological analysis and a variety of fundamental immunological assays will be used to investigate host mechanisms of bystander killing after AAV-P0-ICE injection. This application is novel and innovative in that it utilizes the first viral vector we know of that is restrictively expressed in Schwann-lineage cells hence allowing targeting of schwannomas without neurotoxicity, and proposes investigation of the pathways - tumor and host specific - which underlie induction of bystander tumor killing. Mechanistic understanding of the extensive and specific tumor killing induced by AAV-P0-ICE injection into schwannomas has the potential lead to novel treatment strategies for NF1, NF2 and schwannomatosis, as well as, a variety of other neoplasms.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1073/pnas.2202719119
发表时间:
2022-06-14
期刊:
Proceedings of the National Academy of Sciences of the United States of America
影响因子:
11.1
作者:
[]
通讯作者:
Correction to: Schwannoma gene therapy by adeno-associated virus delivery of the pore-forming protein Gasdermin-D.
更正:通过腺相关病毒递送成孔蛋白 Gasdermin-D 进行神经鞘瘤基因治疗。
DOI:
10.1038/s41417-019-0096-8
发表时间:
2020
期刊:
Cancer gene therapy
影响因子:
6.4
作者:
[Ahmed,SherifG, Abdelanabi,Ahmed, Doha,Mohamed, Brenner,GaryJ]
通讯作者:
Brenner,GaryJ
Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)
-
批准号:10267742
-
项目类别:
-
资助金额:$19.86万
-
财政年份:2020
-
负责人:GARY JAY BRENNER
-
依托单位:
Mechanisms of Caspase-1 Mediated Schwannoma Regression
-
批准号:8703827
-
项目类别:
-
资助金额:$36.02万
-
财政年份:2012
-
负责人:GARY JAY BRENNER
-
依托单位:
Mechanisms of Caspase-1 Mediated Schwannoma Regression
-
批准号:8421092
-
项目类别:
-
资助金额:$36.41万
-
财政年份:2012
-
负责人:GARY JAY BRENNER
-
依托单位:
Mechanisms of Caspase-1 Mediated Schwannoma Regression
-
批准号:8554387
-
项目类别:
-
资助金额:$35.11万
-
财政年份:2012
-
负责人:GARY JAY BRENNER
-
依托单位:
NMDA Receptor Phosphorylation and Trafficking after Pain
-
批准号:7099536
-
项目类别:
-
资助金额:$17.07万
-
财政年份:2002
-
负责人:GARY JAY BRENNER
-
依托单位:
NMDA Receptor Phosphorylation and Trafficking after Pain
-
批准号:6508520
-
项目类别:
-
资助金额:$17.07万
-
财政年份:2002
-
负责人:GARY JAY BRENNER
-
依托单位:
NMDA Receptor Phosphorylation and Trafficking after Pain
-
批准号:6931047
-
项目类别:
-
资助金额:$17.07万
-
财政年份:2002
-
负责人:GARY JAY BRENNER
-
依托单位:
NMDA Receptor Phosphorylation and Trafficking after Pain
-
批准号:6779216
-
项目类别:
-
资助金额:$17.07万
-
财政年份:2002
-
负责人:GARY JAY BRENNER
-
依托单位:
NMDA Receptor Phosphorylation and Trafficking after Pain
-
批准号:6631457
-
项目类别:
-
资助金额:$17.07万
-
财政年份:2002
-
负责人:GARY JAY BRENNER
-
依托单位:
DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY
-
批准号:2241228
-
项目类别:
-
资助金额:$3.46万
-
财政年份:1994
-
负责人:GARY JAY BRENNER
-
依托单位:
DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY
-
批准号:2241227
-
项目类别:
-
资助金额:$2.85万
-
财政年份:1993
-
负责人:GARY JAY BRENNER
-
依托单位:
DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY
-
批准号:3024095
-
项目类别:
-
资助金额:$2.67万
-
财政年份:1992
-
负责人:GARY JAY BRENNER
-
依托单位:
DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY
-
批准号:3024096
-
项目类别:
-
资助金额:$2.73万
-
财政年份:1992
-
负责人:GARY JAY BRENNER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: